Spondyloarthritis: State of the art and future perspectives

Annals of the Rheumatic Diseases

Volumn 69, Issue 6, 2010, Pages 949-954

  Van Der Heijde, Désirée ^a   Maksymowych, Walter P ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYTOKINE RECEPTOR ANTAGONIST; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; BACKACHE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; FATIGUE; GENETICS; HUMAN; IMAGING; JOINT STIFFNESS; MYELITIS; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHEUMATOID ARTHRITIS; SACROILIITIS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SPONDYLARTHRITIS; SPONDYLOARTHROPATHY; TISSUE REPAIR; WELLBEING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; GENETIC PREDISPOSITION TO DISEASE; HLA-B27 ANTIGEN; HUMANS; MAGNETIC RESONANCE IMAGING; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; SPONDYLARTHRITIS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77953700022     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.119529     Document Type: Review

References (69)

1. IMGT/HLA Database. http://www.ebi.ac.uk/cgi-bin/imgt/hla/allele.cgi. (accessed 12 November 2009)
2. Brown MA. Genetics and the pathogenesis of ankylosing spondylitis. Curr Opin Rheumatol 2009;21:318-23.
3. Olivieri I, D'Angelo S, Scarano E, et al. The HLA-B*2709 subtype in a woman with early ankylosing spondylitis. Arthritis Rheum 2007;56:2805-7.
4. Cauli A, Vacca A, Mameli A, et al. A Sardinian patient with ankylosing spondylitis and HLA-B*2709 co-occurring with HLA-B*1403. Arthritis Rheum 2007;56:2807-9.
5. Hou TY, Chen HC, Chen CH, et al. Usefulness of human leucocyte antigen-B27 subtypes in predicting ankylosing spondylitis: Taiwan experience. Intern Med J 2007;37:749-52.
6. D'Amato M, Fiorillo MT, Carcassi C, et al. Relevance of residue 116 of HLAB-27 in determining susceptibility to ankylosing spondylitis. Eur J Immunol 1995;25:3199-201.
7. Sims AM, Barnardo M, Herzberg I, et al. Non-B27 MHC associations of ankylosing spondylitis. Genes Immun 2007;8:115-23.
8. WTCCC, TASC. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329-37.
9. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-3.
10. Cargill M, Schrodi SJ, Chang M, et al. A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007;80:273-90.
11. Rueda B, Orozco G, Raya E, et al. The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis. Ann Rheum Dis 2008;67:1451-4.
12. Rahman P, Inman RD, Gladman DD, et al. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008;58:1020-5.
13. Chang SC, Momburg F, Bhutani N, et al. The ER aminopeptidase, ERAP1, trims precursors to lengths of MHC class I peptides by a "molecular ruler" mechanism. Proc Natl Acad Sci USA 2005;102:17107-12.
14. Cui X, Hawari F, Alsaaty S, et al. Identification of ARTS-1 as a novel TNFR1-binding protein that promotes TNFR1 ectodomain shedding. J Clin Invest 2002;110:515-26.
15. Cui X, Rouhani FN, Hawari F, et al. An aminopeptidase, ARTS-1, is required for interleukin-6 receptor shedding. J Biol Chem 2003;278:28677-85.
16. Cui X, Rouhani FN, Hawari F, et al. Shedding of the type II IL-1 decoy receptor requires a multifunctional aminopeptidase, aminopeptidase regulator of TNF receptor type 1 shedding. J Immunol 2003;171:6814-19. (Pubitemid 37532116)
17. Maksymowych WP, Inman RD, Gladman DD, et al. Association of a specific ERAP1/ARTS1 haplotype with disease susceptibility in ankylosing spondylitis. Arthritis Rheum 2009;60:1317-23.
18. Timms AE, Crane AM, Sims AM, et al. The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004;75:587-95.
19. Maksymowych WP, Rahman P, Reeve JP, et al. Association of the IL1 gene cluster with susceptibility to ankylosing spondylitis: an analysis of three Canadian populations. Arthritis Rheum 2006;54:974-85.
20. Sims AM, Timms AE, Bruges-Armas J, et al. Prospective meta-analysis of interleukin 1 gene complex polymorphisms confirms associations with ankylosing spondylitis. Ann Rheum Dis 2008;67:1305-9.
21. Tran TM, Dorris ML, Satumtira N, et al. Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats. Arthritis Rheum 2006;54:1317-27.
22. Taurog JD, Dorris ML, Satumtira N, et al. Spondylarthritis in HLA-B27/human beta2-microglobulin-transgenic rats is not prevented by lack of CD8. Arthritis Rheum 2009;60:1977-84.
23. Hülsmeyer M, Fiorillo MT, Bettosini F, et al. Dual, HLA-B27 subtype-dependent conformation of a self-peptide. J Exp Med 2004;199:271-81.
24. Mear JP, Schreiber KL, Münz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. J Immunol 1999;163:6665-70.
25. Galocha B, de Castro JA. Folding of HLA-B27 subtypes is determined by the global effect of polymorphic residues and shows incomplete correspondence to ankylosing spondylitis. Arthritis Rheum 2008;58:401-12.
26. Kollnberger S, Bird L, Sun MY, et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 2002;46:2972-82.
27. Santos SG, Lynch S, Campbell EC, et al. Induction of HLA-B27 heavy chain homodimer formation after activation in dendritic cells. Arthritis Res Ther 2008;10:R100.
28. Kollnberger S, Chan A, Sun MY, et al. Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide. Eur J Immunol 2007;37:1313-22.
29. Laloux L, Voisin MC, Allain J, et al. Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2001;60:316-21.
30. Appel H, Kuhne M, Spiekermann S, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006;54:1805-13.
31. Zhang Y, Guerassimov A, Leroux JY, et al. Arthritis induced by proteoglycan aggrecan G1 domain in BALB/c mice. Evidence for t cell involvement and the immunosuppressive influence of keratan sulfate on recognition of t and b cell epitopes. J Clin Invest 1998;101:1678-86.
32. Shi S, Ciurli C, Cartman A, et al. Experimental immunity to the G1 domain of the proteoglycan versican induces spondylitis and sacroiliitis, of a kind seen in human spondylarthropathies. Arthritis Rheum 2003;48:2903-15.
33. Kuhne M, Erben U, Schulze-Tanzil G, et al. HLA-B27-restricted antigen presentation by human chondrocytes to CD8+ T cells: potential contribution to local immunopathologic processes in ankylosing spondylitis. Arthritis Rheum 2009;60:1635-46.
34. Atagunduz P, Appel H, Kuon W, et al. HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis. Arthritis Rheum 2005;52:892-901.
35. Baeten D, Demetter P, Cuvelier CA, et al. Macrophages expressing the scavenger receptor CD163: a link between immune alterations of the gut and synovial inflammation in spondyloarthropathy. J Pathol 2002;196:343-50.
36. Armaka M, Apostolaki M, Jacques P, et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 2008;205:331-7.
37. Braun J, Bollow M, Neure L, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
38. Jandus C, Bioley G, Rivals JP, et al. Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides. Arthritis Rheum 2008;58:2307-17.
39. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, et al. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9.
40. van der Heijde D, Landewé R, Einstein S, et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
41. van der Heijde D, Landewé R, Baraliakos X, et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 2008;58:3063-70.
42. van der Heijde D, Salonen D, Weissman BN, et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 2009;11:R127.
43. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9.
44. Lories RJ, Derese I, de Bari C, et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 2007;56:489-97.
45. Diarra D, Stolina M, Polzer K, et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
46. Baraliakos X, Listing J, Rudwaleit M, et al. The relationship between inflammation and new bone formation in patients with ankylosing spondylitis. Arthritis Res Ther 2008;10:R104.
47. Maksymowych WP, Chiowchanwisawakit P, Clare T, et al. Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 2009;60:93-102.
48. van der Heijde D, Landewé R, Baraliakos X, et al. MRI-inflammation of the vertebral unit (vu) only marginally contributes to new syndesmophyte formation in that unit: a multi-level analysis. Ann Rheum Dis 2008;58(Suppl II):130.
49. Chiowchanwisawakit P, Pedersen, SJ, Lambert RGW, et al. Resolution of inflammation following treatment of ankylosing spondylitis is associated with new bone formation: confirmation of the TNF brake hypothesis. Ann Rheum Dis 2009;68(Suppl 3):126.
50. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
51. Rudwaleit M, Jurik AG, Hermann KG, et al. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. Ann Rheum Dis 2009;68:1520-7.
52. Braun J, Landewé R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
53. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
54. Rudwaleit M, Schwarzlose S, Listing J, et al. Is there a place for magnetic resonance imaging (MRI) in predicting a major clinical response (BASDAI 50%) to TNF alpha blockers in ankylosing spondylitis? Arthritis and Rheum 2003;50:S211-12.
55. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. Arthritis Rheum 2005;53:502-9.
56. Calin A, Mackay K, Santos H, et al. A new dimension to outcome: application of the Bath Ankylosing Spondylitis Radiology Index. J Rheumatol 1999;26:988-92. (Pubitemid 29195700)
57. Taylor HG, Beswick EJ, Dawes PT. Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 1991;10:43-8.
58. Creemers MC, Franssen MJ, van't Hof MA, et al. Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
59. Rudwaleit M, van der Heijde D, Landewé R, et al. New ASAS classification criteria for peripheral spondyloarthritis. Ann Rheum Dis 2009;(Suppl 2):OP-0168.
60. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009;68:784-8.
61. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68 (Suppl 2):ii1-44.
62. Inman RD, Davis JC Jr, Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12.
63. van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009;68:1811-18.
64. Zochling J, van der Heijde D, Burgos-Vargas R, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006;65:442-52.
65. Braun J, Davis J, Dougados M, et al. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
66. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91.
67. Davis JC Jr, Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003;48:3230-6.
68. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
69. Wanders A, Heijde D, Landewé R, et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 2005;52:1756-65.